Werewolf Therapeutics
61 articles about Werewolf Therapeutics
-
UPDATE -- Werewolf Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2023
3/16/2023
Werewolf Therapeutics, Inc. today announced the publication of abstracts for upcoming poster presentations at the American Association for Cancer Research (AACR) Annual Meeting 2023, taking place April 14-19.
-
Werewolf Therapeutics Announces Upcoming Presentation at AACR Annual Meeting 2023
3/15/2023
Werewolf Therapeutics, Inc. today announced the publication of an abstract summarizing an upcoming poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2023.
-
Werewolf Therapeutics Announces Initiation of Patient Dosing in Phase 1 Study of WTX-330
2/24/2023
Werewolf Therapeutics today announced that the first patient has been dosed in a Phase 1 clinical trial evaluating WTX-330.
-
Werewolf Therapeutics to Present at the SVB Securities Global Biopharma Conference
2/7/2023
Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL) today announced that Randi Isaacs, M.D., Chief Medical Officer of Werewolf, will present virtually at 8:40AM ET on February 16th at the SVB Securities Global Biopharma Conference, taking place February 14th -16th , 2023.
-
Werewolf Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
11/10/2022
Werewolf Therapeutics, Inc. provided a business update and reported financial results for the third quarter ended September 30, 2022.
-
Werewolf Therapeutics Presents Preclinical Data on mWTX-330, a Surrogate IL-12 INDUKINE™ Molecule, at the Society for Immunotherapy of Cancer Annual Meeting
11/10/2022
Werewolf Therapeutics, Inc. today announced that it will present preclinical data on mWTX-330, a mouse surrogate of its interleukin-12 (“IL-12”) INDUKINETM product candidate, WTX-330, at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (“SITC”) being held November 8-12, 2022, in Boston, and virtually.
-
Werewolf Therapeutics to Present Preclinical Data at Society for Immunotherapy of Cancer Annual Meeting and Participate in Upcoming Investor Conferences
11/7/2022
Werewolf Therapeutics, Inc. announced upcoming oncology research and investor community events in which Werewolf scientists and management will participate.
-
Werewolf Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Highlights
8/11/2022
Werewolf Therapeutics, Inc. today provided a business update and reported financial results for the second quarter ended June 30, 2022.
-
Werewolf Therapeutics to Participate in a Fireside Chat at the Jefferies Global Healthcare Conference
6/6/2022
Werewolf Therapeutics, Inc. announced that Randi Isaacs, M.D., Chief Medical Officer of Werewolf, will participate in a fireside chat at 9:00AM ET on June 9 during the Jefferies Global Healthcare Conference taking place June 8-10, 2022 in New York, NY.
-
Werewolf Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Highlights
5/10/2022
Werewolf Therapeutics, Inc. provided a business update and reported financial results for the quarter ended March 31, 2022.
-
The deal marks the first immuno-oncology program for Jazz Pharma. With it, they are trying to become a leading oncology company. Here's more about their success.
-
Jazz Pharmaceuticals and Werewolf Therapeutics Announce Exclusive Global License and Collaboration Agreement to Develop WTX-613, a Differentiated, Conditionally-Activated IFNα INDUKINE™ Molecule
4/7/2022
Jazz Pharmaceuticals plc and Werewolf Therapeutics, Inc. today announced that the companies have entered into a licensing agreement under which Jazz has acquired exclusive global development and commercialization rights to Werewolf's investigational WTX-613.
-
Werewolf Therapeutics Reports Fourth Quarter 2021 and Full Year 2021 Financial Results and Provides Business Highlights
3/24/2022
Werewolf Therapeutics, Inc., an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, provided a business update and reported financial results for the fourth quarter and full year ended December 31, 2021.
-
Werewolf Therapeutics Announces Publication of Data Demonstrating the Preclinical Efficacy of WTX-124 in Delivering IL-2 Selectively to the Tumor Microenvironment
3/16/2022
Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics, announced the publication in Cancer Immunology Research of preclinical data for its lead molecule WTX-124, a systemically delivered Interleukin-2 (IL-2) INDUKINE™ molecule.
-
Werewolf Therapeutics Announces Upcoming Presentations at AACR 2022 Annual Meeting
3/15/2022
Werewolf Therapeutics, Inc. announced the publication of two abstracts summarizing upcoming poster presentations at the American Association for Cancer Research Annual Meeting.
-
Werewolf Therapeutics to Present at the SVB Leerink Global Healthcare Conference
2/8/2022
Werewolf Therapeutics, Inc. announced that management will present at the SVB Leerink Global Healthcare Conference taking place virtually from February 14-18, 2022.
-
Werewolf Therapeutics is designing and developing molecules that unleash the natural ferocity of cytokines for the treatment of cancer.
-
Werewolf Therapeutics to Present at the H.C. Wainwright Bioconnect Conference
1/5/2022
Werewolf Therapeutics, Inc. announced that management will present at the H.C. Wainwright Bioconnect Conference, taking place virtually from January 10-13, 2022.
-
Werewolf Therapeutics Added to the Nasdaq Biotechnology Index
12/14/2021
Werewolf Therapeutics, Inc. announced that it has been added to the Nasdaq Biotechnology Index, effective prior to market open on Monday, December 20, 2021.
-
Werewolf Therapeutics to Present Preclinical Data on INDUKINE™ Molecules at the 63rd American Society of Hematology (ASH) Annual Meeting
12/1/2021
Werewolf Therapeutics, Inc. today announced the Company will present preclinical data demonstrating interleukin-12 (IL-12) and interferon-α (IFNα) INDUKINE TM molecules inhibited syngeneic lymphoma tumor growth in mice, induced anti-tumor immune responses and were tolerated in non-human primates.